EQA Programme and prices 2025 – ECAT

EQA Programme and prices 2025

ECAT > EQA Programme > EQA Programme and prices 2025

PROGRAMME AND PRICES 2025

You can download the programme and prices here as a pdf “ECAT Programme and prices 2025“
# Prices are excluding VAT and including shipping costs by regular service.

ANNUAL SUBSCRIPTION
Mandatory for each participant.
Description	Price (Euro) #	Product code
Annual Subscription Fee	158.00	101

MAIN PROGRAMME
Description	Num-ber of sur-veys	Survey(s) 2025				Price (Euro)#	Product code
Description	Num-ber of sur-veys	M1	M2	M3	M4	Price (Euro)#	Product code
Thrombophilia – I: Antithrombin (activity and antigen), Protein C (activity [chromogenic and clotting] and antigen), Protein S activity, Protein S antigen (total and free)	4	√	√	√	√	430.00	402
Thrombophilia – II APC Resistance	4	√	√	√	√	175.00	417
Coagulation Factor – I Factor VIII (clot and chromogenic activity), IX (clot and chromogenic activity), XI:C and XII:C	4	√	√	√	√	220.00	406
Coagulation Factor – II Factor II:C, V:C, VII:C and X:C	4	√	√	√	√	220.00	407
Von Willebrand Factor parameters (antigen, ristocetin cofactor activity, activity, collagen binding, multimers, Factor VIII)	4	√	√	√	√	326.00	408
ADAMTS13 – I (activity and antigen)	4	√	√	√	√	230.00	409
ADAMTS13 – II (antibodies)	2		√		√	150.00	410
ADAMTS13 – III (functional inhibitor)	2		√		√	196.00	419
Factor XIII (activity and antigen)	4	√	√	√	√	162.00	411
Fibrinolysis – I Plasminogen, Antiplasmin	4	√	√	√	√	158.00	412
Fibrinolysis – II t-PA, PAI-1	4	√	√	√	√	158.00	413

LUPUS PROGRAMME
Description	Num-ber of sur-veys	Survey(s) 2025				Price (Euro)#	Product code
		L1	L2	L3	L4
Lupus Anticoagulant / Antiphospholipid Antibodies	4	√	√	√	√	210.00	404

D-DIMER PROGRAMME
Description	Num-ber of sur-veys	Survey(s) 2025				Price (Euro) #	Product code
		D1	D2	D3	D4
D-Dimer	4	√	√	√	√	160.00	405

SCREEN PROGRAMME
Description	Num-ber of sur-veys	Survey(s) 2025								Price (Euro)#	Product code
Description	Num-ber of sur-veys	S1	S2	S3	S4	S5	S6	S7	S8	Price (Euro)#	Product code
Screen-I: APTT, PT/INR and Fibrinogen	8	√	√	√	√	√	√	√	√	276.00	501
Screen-II: Thrombin Time, Reptilase Time	8	√	√	√	√	√	√	√	√	276.00	502

APTT / PT MIXING TEST PROGRAMME
Description	Num-ber of sur-veys	Survey(s) 2025				Price (Euro)#	Product code
		Mix-1	Mix-2	Mix-3	Mix-4
APTT / PT Mixing Test	4	√	√	√	√	230.00	503

HAEMOPHILIA PROGRAMME
Description	Num-ber of sur-veys	Survey(s) 2025				Price (Euro)#	Product code
Description	Num-ber of sur-veys	H1	H2	H3	H4	Price (Euro)#	Product code
Haemophilia Factor VIII (clot and chromogenic activity), Factor IX (clot and chromogenic activity)	4	√	√	√	√	278.00	418
Factor VIII inhibitor	2		√		√	218.00	202
Factor IX Inhibitor	2	√		√		218.00	201
Emicizumab	2		√		√	218.00	223
Kovaltry (Bayer)	2	√		√		215.00	228
Jivi (Bayer)	2	√		√		215.00	229
Esperoct (Novo Nordisk)	2		√		√	215.00	230
NovoEight (Novo Nordisk)	2		√		√	215.00	231
Reflexia (Novo Nordisk)	2		√		√	215.00	232

FDP PROGRAMME
Description	Num-ber of sur-veys	Survey(s) 2025				Price (Euro)#	Product code
Description	Num-ber of sur-veys	F1	F2	F3	F4	Price (Euro)#	Product code
Fibrin(ogen) Degradation Products	4	√	√	√	√	160.00	420
ANTICOAGULATION PROGRAMME
Description	Num-ber of sur-veys	Survey(s) 2025				Price (Euro)#	Product code
Description	Num-ber of sur-veys	A1	A2	A3	A4	Price (Euro)#	Product code
Unfractionated Heparin Monitoring (anti-Xa)	4	√	√	√	√	142.00	414
Low-Molecular Weight Heparin Monitoring (anti-Xa)	4	√	√	√	√	142.00	415
Orgaran (anti-Xa)	2		√		√	72.00	205
Fondaparinux (anti-Xa)	2		√		√	72.00	206
Rivaroxaban (anti-Xa)	2		√		√	72.00	207
Apixaban (anti-Xa)	2		√		√	72.00	208
Edoxaban (anti-Xa)	2		√		√	72.00	221
Argatroban (anti-IIa, dTT)	2		√		√	72.00	209
Dabigatran (anti-IIa, dTT)	2		√		√	72.00	210

THROMBOELASTOGRAPHY PROGRAMME
Description	Num-ber of sur-veys	Survey(s) 2025				Price (Euro) #	Product code
Description	Num-ber of sur-veys	T1	T2	T3	T4	Price (Euro) #	Product code
ROTEM delta ∗ 1 instrument / 1 set of samples ROTEM ∗ 2 instruments / 2 sets of samples ROTEM ∗ 3 instruments / 3 sets of samples ROTEM	4	√	√	√	√	362.00 615.40 868.80	212 213 214
ROTEM sigma ∗ 1 instrument / 1 set of samples ROTEM ∗ 2 instruments / 2 sets of samples ROTEM ∗ 3 instruments / 3 sets of samples ROTEM	4	√	√	√	√	362.00 615.40 868.80	215 216 217
TEG ∗ 1 instrument / 1 set of samples TEG ∗ 2 instruments / 2 sets of samples TEG ∗ 3 instruments / 3 sets of samples TEG	4	√	√	√	√	362.00 615.40 868.80	218 219 220
CLOT-PRO ∗ 1 instrument / 1 set of samples CLOT-PRO ∗ 2 instruments / 2 sets of samples CLOT-PRO ∗ 3 instruments / 3 sets of samples CLOT-PRO	4	√	√	√	√	362.00 615.40 868.80	224 225 226

THROMBIN GENERATION PROGRAMME
Description	Num-ber of sur-veys	Survey(s) 2025				Price (Euro)#	Product code
		TG1	TG2	TG3	TG4
Thrombin Generation Test	2	√		√		164.00	203

PFA PROGRAMME
Description	Num-ber of sur-veys	Survey(s) 2025				Price (Euro)#	Product code
		P1	P2	P3	P4
PFA – 100/200	2	√		√		516.00	222
LTA PROGRAMME
Description	Num-ber of sur-veys	Survey(s) 2025				Price (Euro)#	Product code
		LTA1	LTA2	LTA3	LTA4
Platelet Light Transmission Aggregometry	2		√		√	400.00	233

HIT PROGRAMME
Description	Num-ber of sur-veys	Survey(s) 2025				Price (Euro) #	Product code
Description	Num-ber of sur-veys	HIT1	HIT2	HIT3	HIT4	Price (Euro) #	Product code
HIT – I (immunological testing)	2	√		√		246.00	204
HIT – II (functional testing)	2		√		√	295.00	234

ACT PROGRAMME
Note: samples will be distributed separately from other surveys. For details see Survey Schedule 2025
Description	Num-ber of sur-veys	Survey(s) 2025				Price (Euro)#	Product code
			ACT1		ACT2
Activated Clotting Time	2		√		√	140.00	504

POCT INR QC PROGRAMME
No annual subscription fee applicable if only participating in the POCT INR QC Programme
Description	Num-ber of sur-veys	Survey(s) 2025				Price (Euro)#	Product code
		Q1	Q2	Q3	Q4
POCT INR QC Programme for CoaguChek INR monitors (any type)	4	√	√	√	√	494.00	301
* Annual shipping costst for countries outside Europe: on request

OTHER SURVEYS
Description	Organised by	Num- ber of sur- veys	Survey period(s) 2024	Price (Euro) #	Product code
Post Analytical Platelet Function EQA (electronic survey)	Nascola, USA	2	Spring, Autumn	262.00	701
Platelet Dense Granule exercise (electronic survey)	Nascola, USA	2	Spring, Autumn	262.00	704
Whole Blood Impendance Platelet Aggregation (electronic survey)	Nascola, USA	2	Spring, Autumn	230.00	707
Case study on bleeding disorders (will be distributed together with survey 2025-3)	ECAT	1	2025-3	120.00	703
Case study on anticoagulation bridging (will be distributed together with survey 2025-2)	ECAT	1	2025-2	120.00	706
Pre- and post-analytical electronic survey in haemostasis	ECAT	1	Autumn	85.00	705

HOMOCYSTEINE PROGRAMME (in co-operation with the DEKS, Denmark)
Description	Num-ber of sur-veys	Survey(s) 2025				Price (Euro)#	Product code
		01	02	03	04
Homocysteine	4	√	√	√	√	195.00	1001

MOLECULAR BIOLOGY (in co-operation with the SPMD, Germany)
MOLECULAR GENETICS MG1
Survey name	Description	Num- ber of sur- veys	Surveys 2025		Price (Euro) #	Product code
Survey name	Description	Num- ber of sur- veys	MG1 1/25	MG1 2/25	Price (Euro) #	Product code
MG1 Set A	For details: see below	2	√	√	114.00	601
MG1 Set B	For details: see below	2	√	√	114.00	602
MG1 Set C	For details: see below	2	√	√	114.00	603
MG1 Set D	For details: see below	2	√	√	114.00	604
MG1 Set E	For details: see below	2	√	√	114.00	605
MG1 Set F	For details: see below	2	√	√	114.00	606
MOLECULAR GENETICS MG2
Survey name	Description	Num- ber of sur- veys	Surveys 2025		Price (Euro) #	Product code
Survey name	Description	Num- ber of sur- veys	MG2 1/25	MG2 2/25	Price (Euro) #	Product code
MG2 Set A	For details: see below	2	√	√	114.00	801
MG2 Set B	For details: see below	2	√	√	114.00	802
MG2 Set C	For details: see below	2	√	√	114.00	803
MG2 Set D	For details: see below	2	√	√	114.00	804
MG2 Set E	For details: see below	2	√	√	114.00	805
MG2 Set F	For details: see below	2	√	√	114.00	806

DNA SEQUENCING
Survey name	Description	Num- ber of sur- veys	Surveys 2025		Price (Euro) #	Product code
			SQ 1/25	SQ 2/25
SQ	DNA Sequencing (Sequencing and corresponding diagnostic interpretation)	2	√	√	266.00	901
DNA ISOLATION
Survey name	Description	Num-ber of sur-veys	Surveys 2025		Price (Euro) #	Product code
			DI 1/25	DI 2/25
DI	DNA Isolation and genotyping For details: see below	2	√	√	141.00	902

Extra costs for shipment of Molecular Biology surveys	Per registration for one or more of the Molecular Biology surveys an annual fee of € 68.50 will be charged.

Details MG1

Set A:
– FV-Leiden (F5, NM_000130.5:c.1601G>A, rs6025)
– FII g20210a (F2, NM_000506.5:c.*97G>A, rs1799963)
Methylenetetrahydrofolate reductase (MTHFR)
– MTHFR C677T (MTHFR, NM_005957.5:c.665C>T, rs1801133)
– MTHFR A1298C (MTHFR, NM_005957.5:c.1286A>C, rs1801131)
– PAI-I 4G5G (SERPINE1, NM_000602.5:c.-820G[(4_5)], rs1799762

Set B:
– FXIII V34L (F13A1, NM_000129.4:c.103G>T, rs5985)
– GPIIIa (ITGB3, NM_000212.3:c.176T>C, rs5918)
– beta-Fibrinogen g-455a (FGB, NM_005141.4:c.-463G>A, rs1800790)
Vitamin K epoxide reductase complex subunit 1 (VKORC1)
– VKORC1 G-1639 (VKORC1, NM_024006.6:c.-1639G>A, rs9923231)
– VKORC1 C1173T (VKORC1, NM_024006.6:c.174-136C>T, rs9934438)
– FXII c46t (F12, NM_000505.4:c.-4T>C rs1801020)
– FV-H1299R (F5, NM_000130.5:c.3980A>G, rs1800595)

Set C:
Alpha-1-Antitrypsin, (serpin family A member1)
– AAT-PIS (SERPINA1, NM_000295.5:c.863A>T, rs17580)
– AAT-PIZ (SERPINA1, NM_000295.5:c.1096G>A, rs28929474)
– AAT – Genotyping
– AAT- (Alpha-1-Antitrypsin-Genotyping)
Apolipoprotein E (APOE)
– ApoE2 (APOE, NM_000041.4:c.526C>T, rs7412)
– ApoE4 (APOE, NM_000041.4:c.388T>C, rs429358)
– ApoE – Genotyping
– ApoB100 (APOB, NM_000384.3:c.10580G>A, rs5742904)
– ACE I/D (ACE, NM_000789.3:c.2306-117_2306-116insAF118569.1:g.14094_14382, rs1799752)
– CETP B1/B2 (CETP, NM_000078.3:c.118+279G>A, rs708272

Set D:
Aldolase, fructose-bisphosphate B (ALDOB )
– AldoB 149 (ALDOB, NM_000035.4:c.448G>C, rs1800546)
– AldoB 174 (ALDOB, NM_000035.4:c.524C>A, rs76917243)
– AldoB 334 (ALDOB, NM_000035.4:c.1005C>G, rs78340951)
Hereditary Hemochromatosis (HFE)
– HFE H63D (HFE, NM_000410.4:c.187C>G, rs1799945)
– HFE S65C (HFE, NM_000410.4:c.193A>T, rs1800730)
– HFE C282Y (HFE, NM_000410.4:c.845G>A, rs1800562)
– LCT c-13910t (LCT, NM_005915.6:c.1917+326C>T, rs4988235)
Nucleotide binding oligomerization domain containing 2 (NOD2)
– NOD R702W (NOD2, NM_001370466.1:c.2023C>T, rs2066844)
– NOD G908R (NOD2, NM_001370466.1:c.2641G>C, rs2066845)
– NOD L1007finsC (NOD2, NM_001370466.1:c.2938dup, rs2066847)

Set E:
– ATP7B-C3207A (ATP7B, NM_000053.4:c.3207C>A, rs76151636)
– FSAP Marburg-I (HABP2, NM_004132.5:c.1601G>A, rs7080536)
– ITGA2 GpIaIIa C807T (ITGA2, NM_002203.4:c.759C>T, rs1126643)
– Col1A1 SP1 (Col1A1, NM_000088.4:c.104-441G>T, rs1800012)
Vitamin D receptor (VDR)
– VDR BsmI (VDR, NM_000376.3:c.1024+283G>A, rs1544410)
– VDR ApaI (VDR, NM_000376.3:c.1025-49G>T, rs7975232)
– VDR TaqI (VDR, NM_000376.3:c.1056T>C, rs731236

Set F:
– Faktor VII (R353Q) (F7, NM_019616.4:c.1172G>A, rs6046)
– AT3 Cambridge Typ I/II (SERPINC1, NM_000488.4:c.1246G>C>T, rs121909548)
– CYP3A5*3 (CYP3A5, NM_000777.5:c.219-237A>G, rs776746)

Details MG2

Set A:
Thiopurine S-methyltransferase (TPMT)
– TPMT2 (TPMT, NM_000367.5:c.238G>C, rs1800462)
– TPMT3B (TPMT, NM_000367.5:c.460G>A, rs1800460)
– TPMT3C (TPMT, NM_000367.5:c.719A>G, rs1142345)
– TPMT – Genotyping
– CYP2C83 (CYP2C8, NM_000770.3:c.1196A>G, rs10509681)
  Cytochrom P450 2C9 (CYP2C9)
– CYP2C92 (CYP2C9, NM_000771.4:c.430C>T, rs1799853)
– CYP2C93 (CYP2C9, NM_000771.4:c.1075A>C, rs1057910)
– CYP2C9 – Genotyping
– UGT1A128 (UGT1A1, NM_000463.3:c.-41_-40dupTA, rs3064744)
Dihydropyrimidine dehydrogenase (DPYD)
– DPYD2A (DPYD, NM_000110.4:c.1905+1G>A, rs3918290)
– DPYD*13 (DPYD, NM_000110.4:c.1679T>G, rs55886062)
– DPYD p.D949V (DPYD, NM_000110.4:c.2846A>T, rs67376798)
– DPYD c.1129-5923C>G (DPYD, NM_000110.4:c.1129-5923C>G, rs75017182)
– DPYD c.1236G>A (DPYD, NM_000110.4:c.1236G>A, rs56038477)
– DPYD HapB3 (DPYD, NM_000110.4:c.1129-5923C>G, rs75017182,
  NM_000110.4:c.1236G>A, rs56038477)
– DPD activity score acc. to CPIC
– DPD activity score acc. to DGHO
– BCHE A (D70G) (BCHE, NM_000055.4:c.293A>G, rs1799807)
– BCHE K (A567T) (BCHE, NM_000055.4:c.1699G>A, rs1803274)

Set B:
– KRAS proto-oncogene, GTPase (KRAS)
– KRAS p.G12/p.G13 (KRAS, NP_004976.2:p.G12/G13)
– KRAS p.G12 (KRAS, NM_004985.5:c.34G>T>C>A, rs121913530)
– KRAS p.G12 (KRAS, NM_004985.5:c.35G>T>C>A, rs121913529)
– KRAS p.G13 (KRAS, NM_004985.5:c.37G>T>C>A, rs121913535)
– KRAS p.G13 (KRAS, NM_004985.5:c.38G>T>C>A, rs112445441)
– KRAS p.G12 (KRAS, NP_004976.2:p.G12)
– KRAS p.G12 (KRAS, NM_004985.5:c.34G>T>C>A, rs121913530)
– KRAS p.G12 (KRAS, NM_004985.5:c.35G>T>C>A, rs121913529)
– KRAS p.G13 (KRAS, NP_004976.2:p.G13)
– KRAS p.G13 (KRAS, NM_004985.5:c.37G>T>C>A, rs121913535)
– KRAS p.G13 (KRAS, NM_004985.5:c.38G>T>C>A, rs112445441)
– KRAS p.Q61 (KRAS, NP_004976.2:p.Q61)
– KRAS p.Q61 (KRAS, NM_004985.5:c.181C>G>A, rs121913238)
– KRAS p.Q61 (KRAS, NM_004985.5:c.182A>T>G>C, rs121913240)
– KRAS p.Q61 (KRAS, NM_004985.5:c.183A>T>C, rs17851045)
– BRAF p.V600 (BRAF, NP_004324.2:p.V600E/K)
– BRAF V600E (BRAF, NM_004333.6:c.1799T>A, rs113488022)
– BRAF V600K (BRAF, NM_004333.6:c.1798_1799delinsAA, rs121913227)
c-KIT p.D816V (KIT, NM_000222.3:c.2447A>T, rs121913507)
– NRAS (NRAS, NP_002515.1:p.Q61)
– NRAS (NRAS, NM_002524.5:c.181C>T>G>A, rs121913254)
– NRAS (NRAS, NM_002524.5:c.182A>T>G>C, rs11554290)
– NRAS (NRAS, NM_002524.5:c.183A>T>C, rs121913255)

Set C:
– HLA-B*27:01 (HLA-B, NM_005514.8)
– TNF alpha 238 (TNF, NM_000594.3:c.-418G>A, rs361525)
– TNF alpha 308 (TNF, NM_000594.3:c.-488G>A, rs1800629)

Set D:
– Cytochrome P450 2D6 (CYP2D6)
– CYP2D62-296 (CYP2D62, NM_000106.6:c.886C>T, rs16947)
– CYP2D62-486 (CYP2D62, NM_000106.6:c.1457G>C, rs1135840)
– CYP2D63 (CYP2D63, NM_000106.6:c.775del, rs35742686)
– CYP2D64 (CYP2D64, NM_000106.6:c.506-1G>A, rs3892097)
– CYP2D66 (CYP2D66, NM_000106.6:c.454del, rs5030655)
– CYP2D67 (CYP2D67, NM_000106.6:c.971A>C, rs5030867)
– CYP2D68 (CYP2D68, NM_000106.6:c.505G>T, rs5030865)
– CYP2D69 (CYP2D69, NM_000106.6:c.841_843del, rs5030656)
– CYP2D610 (CYP2D610, NM_000106.6:c.100C>T, rs1065852)
– CYP2D617 (CYP2D617, NM_000106.6:c.320C>T, rs28371706)
– CYP2D635 (CYP2D635, NM_000106.6:c.31G>A, rs769258)
– CYP2D641 (CYP2D641, NM_000106.6:c.985+39G>A, rs28371725)
– CYP2D65 (CYP2D6, Deletion)
– CYP2D6xN (CYP2D6, Duplication/Amplification)
Cytochrome P450 2C19 (CYP2C19)
– CYP2C192 (CYP2C19, NM_000769.4:c.681G>A, rs4244285)
– CYP2C193 (CYP2C19, NM_000769.4:c.636G>A, rs4986893)
– CYP2C19*17 (CYP2C19, NM_000769.4:c.-806C>T, rs12248560)
– CYP2C19 – Genotyping

Set E:
– HLA-B57:01 (HLA-B, NM_005514.8)
Cytochrome P450 2B6 (CYP2B6)
– CYP2B64 (CYP2B6, NM_000767.5:c.785A>G, rs2279343)
– CYP2B69 (CYP2B6, NM_000767.5:c.516G>T, rs3745274)
– CYP2B66 (CYP2B6, NM_000767.5:c.785A>G, rs2279343 + NM_000767.5:c.516G>T, rs3745274)
– ABCB1 c.3435T>C (ABCB1, NM_001348946.2:c.3435T>C, rs1045642)
– CCR5-del32bp (CCR5, NM_001394783.1:c.554_585del, rs333)

Set F:
– IL28B (C/T Polymorphism) (IFNL4, NM_001276254.2:c.151-152G>A, rs12979860)
– IL6 G(-174)C (IL6, NM_000600.4:c.-237C>G, rs1800795)
– CYP3A4*22 (CYP3A4, NM_017460.6:c.522-191C>T, rs35599367)

Details DNA Isolation and genotyping
– FV-Leiden (F5, NM_000130.5:c.1601G>A, rs6025)
– FV-H1299R (F5, NM_000130.5:c.3980A>G, rs1800595)
– FV-Cambridge (F5, NM_000130.5:c.1001G>C, rs118203906)
– FV-Hong-Kong (F5, NM_000130.5:c.1000A>G, rs118203905)
– FII g20210a (F2, NM_000506.5:c.*97G>A, rs1799963)
Methylenetetrahydrofolate reductase (MTHFR)
– MTHFR C677T (MTHFR, NM_005957.5:c.665C>T, rs1801133)
– MTHFR A1298C (MTHFR, NM_005957.5:c.1286A>C, rs1801131)
Hereditary Hemochromatosis (HFE)
– HFE H63D (HFE, NM_000410.4:c.187C>G, rs1799945)
– HFE S65C (HFE, NM_000410.4:c.193A>T, rs1800730)
– HFE C282Y (HFE, NM_000410.4:c.845G>A, rs1800562)